SCHEMBL22337647

SCHEMBL22337647

COc1ccc2ccn(C)c2n1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 4/20 0.50
MTNR1B P49286 4/20 0.50
PDE10A Q9Y233 13/20 0.41
PDE2A O00408 5/20 0.41
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
BRD9 Q9H8M2 1/20 0.36
BRD7 Q9NPI1 1/20 0.36
PDE7A Q13946 3/20 0.35
PDE5A O76074 2/20 0.35
PDE11A Q9HCR9 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4D Q08499 1/20 0.35
PDE3A Q14432 1/20 0.35
PDE7B Q9NP56 1/20 0.35
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20939368 0.77 MTNR1A (0.62) MTNR1AMTNR1BPDE10APDE2APDE7A
SCHEMBL926083 0.75 DDB1 (0.39) DDB1CRBN
SCHEMBL19231458 0.73 MTNR1A (0.46) MTNR1AMTNR1BPDE10ABRD9BRD7
SCHEMBL1150427 0.73 MTNR1A (0.42) MTNR1AMTNR1BPDE10APDE2APDE7A
SCHEMBL7914425 0.72 CCR1 (0.42) PDE10ADDB1CRBNBRD9POLB
SCHEMBL8513409 0.72 MTNR1A (0.41) MTNR1AMTNR1BPDE10APDE2APDE7A
SCHEMBL24394851 0.71 BRD4 (0.39)
SCHEMBL22323347 0.71 DDB1 (0.39) DDB1CRBN
SCHEMBL8513406 0.71 MTNR1A (0.40) MTNR1AMTNR1BPDE10A
SCHEMBL14487895 0.70 MTNR1A (0.61) MTNR1AMTNR1BPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 US disclosed
US-20220106305-A1 BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2022-04-07 US disclosed
WO-2020163193-A1 BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106305-A1 BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS ENGASE, UGGT1, MGAT3 MTNR1A 3361/4885MTNR1B 3495/4885PDE10A 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.